ORYZON to present at the 2nd Neuroscience Innovation Forum in San Francisco

MADRID, SPAIN and CAMBRIDGE MA.

• The company will also participate at the Trout Annual 1x1 Management Access Event 2019 during the week of the JP Morgan Healthcare Conference

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Dr. Carlos Buesa and Dr. Roger Bullock, Oryzon’s CEO and CMO, will present the recent progresses of Vafidemstat, in Phase II clinical development in different CNS indications, at the 2nd Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 6th of January 2019, a day before the JP Morgan meeting. Oryzon’s presentation will take place in Track C at 13:50 PT. Dr. Buesa will also participate as a panelist in a Panel entitled “Progress in Alzheimer’s”.

Click here to see the full Press Release